Shots:

• The approval is based on P-III IKEMA study assessing Sarclisa in combination with carfilzomib and dexamethasone (Kd) in 302 patients with relapsed MM who have received 1 to 3 prior lines of therapy across 69 centers spanning 16 countries
• The addition of Kd in Sarclisa leads to a 47% reduction in the risk of disease progression and death- and the benefit was evident across all patient subgroups
• The approval marks the second indication for the Sarclisa combination regimen for RRMM. Previously- Sarclisa received Health Canada approval in combination with Pd for patients with RRMM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor

  | Ref: Newswire.Ca | Image: Evaluate Pharma